The Conversation: The backlash against Johnson & Johnson’s COVID-19 vaccine is real and risky — here’s exactly how to make the rollout a success

But while many people are excited about the prospects of only one shot, the new vaccine is also getting backlash. Part of that is coming from lack of clarity about the vaccines’ efficacy numbers, and part of it is more nuanced. On March 2, the U.S. Conference of Catholic Bishops urged Catholics to avoid the Johnson & Johnson vaccine because it uses lab-grown cells that are clones of fetal tissue derived from abortions in the 1980s, even as individual Catholic dioceses have provided contrary guidance, as has the Vatican itself. Distribution of the vaccines has also become entangled in racial politics, with some people worried that underserved communities of poor, Black or Latino residents will be sent inferior vaccines.

Don’t miss: Americans debate what COVID-19 vaccine they want, but Fauci says to take what’s available to you

If states don’t plan carefully for how the vaccines are distributed, the result could be a nightmare of frustrated patients and wasted vaccine.

As experts specializing in health-care operations, data analytics and supply-chain management, we have been analyzing COVID-19 vaccine rollout policies. While our research shows there is great promise for the one-dose vaccine, we believe biases against the Johnson & Johnson vaccine cannot be ignored in planning and distribution decisions.

The problem with comparing efficacy numbers

The primary factor complicating acceptance of the Johnson & Johnson vaccine is in the top-line number: It has an efficacy level of 66%, while the other two U.S.-authorized vaccines, made by Pfizer with German partner BioNTech BNTX, +3.70% and by Moderna, have efficacy levels of at least 90%.

From Barron’s: BioNTech says it could supply 3 billion doses of its COVID-19 vaccine next year

Trying to compare those numbers is tricky, though. Experts are quick to point out that the clinical trials were conducted at different times — Pfizer and Moderna conducted their trials before several mutated variants had been reported, whereas Johnson & Johnson’s trials were conducted after that. Consequently, Johnson & Johnson has clinical-trial data to show its vaccine can work effectively against variants first reported in the U.K., South Africa and Brazil.

In terms of preventing severe disease, hospitalization and death, the Johnson & Johnson vaccine is comparable to the Pfizer and Moderna vaccines. With continued shortage of vaccine supply, individuals and vaccinators should take any one of the three vaccines whenever they are available so that they can get sufficient protection sooner.

Coronavirus Update: Biden to buy another 100 million doses of J&J vaccine as Alaska becomes first state to open eligibility to everyone aged 16 and over

Yet, the sheer difference in the top-line numbers makes it difficult to look away. According to a February 2021 Centers for Disease Control and Prevention survey, when offered the choice between a two-dose COVID-19 vaccine, either Pfizer or Moderna, and a one-dose vaccine, Johnson & Johnson’s, nearly 60% of the respondents preferred the two-dose vaccine and only 7% preferred the one-dose vaccine. Among those who preferred two-dose vaccines, 72% said they were willing to wait a month for one of those rather than get the one-dose vaccine now.

Such biases can have real consequences. In the European Union, 80% of the COVID-19 vaccine doses made by AstraZeneca AZN, -1.60% — which also has lower reported efficacy and isn’t authorized in the U.S. — were sitting on the shelves. Many people, including some clinicians, reportedly believe it to be inferior to the Pfizer vaccine.

Four strategies for a successful rollout

A one-dose vaccine with less restrictive storage requirements would be ideal for hard-to-reach rural areas and underserved communities. Meatpacking companies have reached out to officials in North Carolina, for example, and the state plans to target agricultural workers. But distributing only the Johnson & Johnson vaccine now could compound the already deep-seated vaccine hesitancy in some regions.

Policy makers must acknowledge these fears and develop a plan. Here are four strategies for creating as smooth a rollout as possible:

• Let people know which vaccine they will be getting when they book an appointment. That can avoid situations in which people rejecting vaccines at the distribution site, which leads to wasted appointment time slots and potentially wasted vaccine doses. When only the two mRNA vaccines were available, many states did not reveal the vaccine brand when offering appointments, and the public largely perceives the two as interchangeable products.

• Have each vaccination site focus on one type of vaccine, either the Johnson & Johnson vaccine or the Pfizer or Moderna two-dose vaccines to avoid confusion for recipients. Separating vaccine offerings can respect people’s legitimate preferences and avoid last-minute cancellations. Operationally speaking, focusing on a single type of vaccine also simplifies the administration process and prevents handling errors.

• The Johnson & Johnson vaccine is suitable for small-scale and mobile vaccination sites in rural areas and underserved communities, as well as individuals. However, health officials can help avoid some backlash if they ensure people are offered the option to travel a reasonable distance to larger vaccination sites that offer the Pfizer and Moderna vaccines. Letting people make informed decision can avoid public mistrust.

• Instead of avoiding comparing the three vaccines, public health experts should be more transparent in educating the public about the effectiveness of the Johnson & Johnson vaccine. For example, the single-dose vaccine is believed to be 100% effective in preventing hospitalizations and deaths from COVID-19.

The Johnson & Johnson vaccine is a strong boost to the COVID-19 vaccination effort in the U.S. However, it may well lead to frustration and waste if vaccine planners don’t prepare for potential biases against this new vaccine. The focus should be to leverage the three vaccines to achieve herd immunity rapidly so that the U.S. can finally leave the prolonged pandemic behind.

Tinglong Dai is an associate professor of operations management and business analytics at the Johns Hopkins Carey Business School, with a joint faculty appointment at the Johns Hopkins School of Nursing. Christopher S. Tang is a distinguished professor and the holder of the Edward W. Carter Chair in Business Administration at the UCLA Anderson School of Management. Ho-Yin Mak is associate professor in management science (with tenure) at the Saïd Business School, University of Oxford.

This commentary was originally published in The Conversation—Backlash against Johnson & Johnson’s COVID-19 vaccine is real and risky—here’s how to make its rollout a success.